Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial o...

11/20/23

Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema Yahoo Finance

[more]

Feeds Categories:
- Liquidation,
- News